<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Singh CR</submitter><funding>BLRD VA</funding><funding>NICHD NIH HHS</funding><funding>NINDS NIH HHS</funding><funding>NIGMS NIH HHS</funding><pagination>109376</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8363759</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>36(2)</volume><pubmed_abstract>eIF5-mimic protein (5MP) is a translational regulatory protein that binds the small ribosomal subunit and modulates its activity. 5MP is proposed to reprogram non-AUG translation rates for oncogenes in cancer, but its role in controlling non-AUG initiated synthesis of deleterious repeat-peptide products, such as FMRpolyG observed in fragile-X-associated tremor ataxia syndrome (FXTAS), is unknown. Here, we show that 5MP can suppress both general and repeat-associated non-AUG (RAN) translation by a common mechanism in a manner dependent on its interaction with eIF3. Essentially, 5MP displaces eIF5 through the eIF3c subunit within the preinitiation complex (PIC), thereby increasing the accuracy of initiation. In Drosophila, 5MP/Kra represses neuronal toxicity and enhances the lifespan in an FXTAS disease model. These results implicate 5MP in protecting cells from unwanted byproducts of non-AUG translation in neurodegeneration.</pubmed_abstract><journal>Cell reports</journal><pubmed_title>Human oncoprotein 5MP suppresses general and repeat-associated non-AUG translation via eIF3 by a common mechanism.</pubmed_title><pmcid>PMC8363759</pmcid><funding_grant_id>R01 NS099280</funding_grant_id><funding_grant_id>P20 GM103418</funding_grant_id><funding_grant_id>I01 BX004842</funding_grant_id><funding_grant_id>R15 GM124671</funding_grant_id><funding_grant_id>R01 NS086810</funding_grant_id><funding_grant_id>R01 GM064781</funding_grant_id><funding_grant_id>R01 GM124204</funding_grant_id><funding_grant_id>P50 HD104463</funding_grant_id><pubmed_authors>Asano M</pubmed_authors><pubmed_authors>Takasu A</pubmed_authors><pubmed_authors>Todd PK</pubmed_authors><pubmed_authors>Asano I</pubmed_authors><pubmed_authors>Escalante CR</pubmed_authors><pubmed_authors>Asano K</pubmed_authors><pubmed_authors>Gillaspie S</pubmed_authors><pubmed_authors>Nakamura A</pubmed_authors><pubmed_authors>Zou Y</pubmed_authors><pubmed_authors>Jaiswal R</pubmed_authors><pubmed_authors>Thornton M</pubmed_authors><pubmed_authors>Hilgers M</pubmed_authors><pubmed_authors>Aube E</pubmed_authors><pubmed_authors>Singh CR</pubmed_authors><pubmed_authors>Tani N</pubmed_authors><pubmed_authors>Moore C</pubmed_authors><pubmed_authors>Cecil A</pubmed_authors><pubmed_authors>Glineburg MR</pubmed_authors></additional><is_claimable>false</is_claimable><name>Human oncoprotein 5MP suppresses general and repeat-associated non-AUG translation via eIF3 by a common mechanism.</name><description>eIF5-mimic protein (5MP) is a translational regulatory protein that binds the small ribosomal subunit and modulates its activity. 5MP is proposed to reprogram non-AUG translation rates for oncogenes in cancer, but its role in controlling non-AUG initiated synthesis of deleterious repeat-peptide products, such as FMRpolyG observed in fragile-X-associated tremor ataxia syndrome (FXTAS), is unknown. Here, we show that 5MP can suppress both general and repeat-associated non-AUG (RAN) translation by a common mechanism in a manner dependent on its interaction with eIF3. Essentially, 5MP displaces eIF5 through the eIF3c subunit within the preinitiation complex (PIC), thereby increasing the accuracy of initiation. In Drosophila, 5MP/Kra represses neuronal toxicity and enhances the lifespan in an FXTAS disease model. These results implicate 5MP in protecting cells from unwanted byproducts of non-AUG translation in neurodegeneration.</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Jul</publication><modification>2024-11-13T04:13:27.806Z</modification><creation>2022-02-11T08:08:03.381Z</creation></dates><accession>S-EPMC8363759</accession><cross_references><pubmed>34260931</pubmed><doi>10.1016/j.celrep.2021.109376</doi></cross_references></HashMap>